1. Annual Report 2025
  2. Research
  3. GREMPAL

GREMPAL

Primary Care Research Group in Common Disorders of the Musculoskeletal System.

The Primary Care Research Group in Common Disorders of the Musculoskeletal System (Grempal-Group consolidated since 2017) is currently led by Daniel Martínez Laguna and its members are Carlen Reyes, Meritxell Aivar Blanch, Cristina Carbonell Abella, Maria Antònia Pou and César Diaz Torné.

The already established research lines of the group are the epidemiology of osteoporosis and ostheoarthrosis, the fragility fractures and the pharmaco-epidemiology of the most commonly used treatments in primary care.

In addition, a new research line in gout (Maria Antonia Pou) and rheumatoid arthritis (César Diaz Torné) has been recently added. The GREMPAL collaborates with national and international research groups. Nationally, from 2021, with the Real-World Epidemiology group (IDIAP Jordi gol) through the joint hiring of Carlen Reyes as a post-doctoral researcher and in 2023 with the Medicines Unit (IDIAP Jordi Gol) through a project (association of serum vitamin D and fractures) submitted to the health research funds of the Carlos III Institute.

Internationally, the GREMPAL has maintained its already existing collaboration with the University of Oxford through the project Epidemiology and Burden of Imminent Subsequent Fractures in postmenopausal women (2023-2024) and the post-authorizaton studies of the prescription drugs romosozumab (2020-2026) and galcanezumab (2019-2025).

The incorporation of César Diaz Torné to the group will open the door to future collaborations with the rheumatology unit of the Sant Pau hospital and together with Maria Antònia Pou they have created links with the Rheumatology department of the University of Auckland (New Zealand) where they have spent 3 months (2023) as visiting investigadors.

Group projects

  • Validació del diagnòstic de gota en la base de dades de la història clínica informatitzada de l'Atenció Primària. ICS - Institut Català de la Salut. 2022-2025. IP: Maria Antònia Pou Giménez.

  • Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Carlen Reyes Reyes.

  • Tractament de la gota a l´atenció primària de Catalunya. 2024-2027. IP: Maria Antònia Pou Giménez.

  • Iimplementación de una prueba diagnóstica para incrementar la eficacia desde atención primaria en la identificación de pacientes con hipolactasia o deficiencia en lactasa intestinal. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

  • European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.

  • Estudio cualitativo sobre el impacto de la gota en la crianza. 2024-2027. IP: Maria Antònia Pou Giménez.

  • Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes Reyes.

  • Encuesta sobre preferencias de medicación entre pacientes con y en riesgo de enfermedad cardiovascular aterosclerótica (Ecva) en la UE5. Merck Sharp & Dohme de España, S.A.; Oracle Ibérica, S.R.L. 2025-2028. IP: Carlen Reyes Reyes.

  • Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP: Carlen Reyes Reyes.

  • Disseny i validació d'un sistema basat en ia-generativa per al suport a l'assistant clínic a l'atenció primària. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

  • Designing and validating a Real-time Adverse Drug reaction Automated Recognition tool for primary care: the RADAR study. Agència de Gestió d'Ajuts Univ i de Recerca (AGAUR). 2024-2027. IP: Carlen Reyes Reyes.

  • Calidad de vida y necesidades de supervivientes de cáncer en España. Un estudio cuantitativo. Asociación Española Contra el Cáncer; Semfyc (Sociedad Española de Medicina de Familia. 2025-2025. IP: Daniel Martínez Laguna.

  • A Randomized, Double-Blind, Controlled Trial to Evaluate the Efficacy and Safety of a Combination of Xyloglucan and Gelose in the treatment of acute diarrhea in adults. (Xilaplus Af). Noventure, S.L. 2025IP: Carlen Reyes Reyes.

  • ¿Cuál es el Impacto de la Gota en el Empleo? Un Estudio Cualitativo Mediante Entrevistas a Personas con Gota. 2023-2026. IP: Maria Antònia Pou Giménez.

  • Incidencia y asociación entre la exposición a las medicaciones potencialmente inapropiadas de la herramienta Stoppfall y el riesgo de eventos adversos: estudio de cohortes de base poblacional. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Carlen Reyes Reyes.

  • Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana: estudio de base poblacional. 2024-2027. IP: Carlen Reyes Reyes.

  • Models pronòstics de morbimortalitat de la insuficiència cardíaca estable i descompensada en Atenció Primària. (Predoc_Eco-23/8). ICS - Institut Català de la Salut; Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2029. IP: Maria Antònia Pou Giménez,Victoria Cendrós Cámara.

  • Estudi descriptiu de metodologia mixta per ampliar el coneixement de la gota a Catalunya: de les grans bases de dades a la perspectiva del malalt. (PREDOC_ECO-24/8). ICS - Institut Català de la Salut. 2025-2030. IP: Maria Antònia Pou Giménez.

Group publications

  • Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR et al. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025;48(8):1386-1394. PMID:40465422.

  • Rossello M, Giménez M. Innovating from proximity: Reflections from a committed team. Aten. Prim. 2025;57(12):103398-103398. PMID:41187559.

  • Cuadra LLopart L, Zorrilla SS, Martínez Laguna D, Giner M, Aviñó RI, Montoya Garcia MJ et al. Health Outcomes in Fragility Fractures in the Spanish Registry of Osteoporotic Fractures According to the FLS Care Model. Arch. Med. Res. 2026;57(3):103302-103302. PMID:40972141.

  • León García M, Martínez EC, Pérez YÁ, Pou MA, García Franco AL, Bas AS et al. Family physicians' attitudes and practice on screening and prevention of fragility fractures, and shared decision-making with postmenopausal women: a qualitative study in Spain. BMC Prim. Care. 2025;26(1):260-260. PMID:40835900.

  • Reyes C, Pou MA, Diaz Torne C, Carbonell Abella C, Brotons C, Martinez Laguna D. Association of morphine vs. fentanyl prescription dispensation with adverse clinical outcomes. Front. Pharmacol. 2025;161579634-1579634. PMID:40635750.

  • Montoya Garcia MJ, Carbonell Abella C, Garcia MG, Hernández Cruz B, Gómez Vaquero C, Naranjo A et al. Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the Refra Fls-Seiomm Registry. Osteoporosis Int. 2025;36(11):2245-2255. PMID:40938378.

Proceeding Papers

  • Pou MA, Reyes C, Martinez Laguna D, Satorra P, Tebe C, Dalbeth N et al. The Young, the Metabolic and the Hypertensive. A Cluster Analysis of Gout Characteristics and Comorbidities. Ann. Rheum. Dis. 2025;841585-1586.

  • Gómez Puerta JA, Grau M, Tebe C, Frade Sosa B, Sarmiento Monroy J, Carbonell Abella C et al. Prevalence and Incidence of Systemic Lupus Erythematosus in Catalonia Spain. A Population-Based Study. Ann. Rheum. Dis. 2025;84.

  • Gómez Puerta JA, Frade Sosa B, Ponce A, Grau M, Tebe C, Sarmiento Monroy J et al. Is There an Increase in the Prevalence and Incidence Rates of Rheumatoid Arthritis in Catalonia, Spain: A Population-Based Study (2006-2021). Ann. Rheum. Dis. 2025;84.

  • Gómez Puerta JA, Ramírez J, Ponce A, Azuaga A, Grau M, Tebe C et al. Increase in Prevalence and Incidence Rates of Psoriatic Arthritis in Catalonia, Spain: A Population-Based Study. Ann. Rheum. Dis. 2025;84.

  • Pou MA, Reyes C, Martinez Laguna D, Tebe C, Satorra P, Dalbeth N et al. Gout Characteristics, Comorbidities and Management in a Long Primary Care Database From Catalonia: The Gotap Study. Ann. Rheum. Dis. 2025;841582-1583.

  • Gomez Puerta J, Tebe C, Grau M, Sosa BF, Sarmiento Monroy JC, Carbonell Abella C et al. Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain. Arthritis Rheumatol. 2025;771957-1959.

  • Sarmiento Monroy J, Grau M, Tebe C, Carbonell Abella C, Martinez Laguna D, Frade Sosa B et al. Epidemiology of Sjogren Syndrome in Catalonia Spain. A Population-Based Cohort Study. Ann. Rheum. Dis. 2025;84.

  • Mercadé Besora N, Raventós B, Trinh N, Li H, Hayati S, Giuliodori A et al. Effectiveness of Covid-19 Primary and Booster Vaccination During Pregnancy: A Target Trial Emulation and Meta-Analysis of Data From 4 European Countries. Gac. Sanit. 2025;39.

Anar a l'inici